migraine

Toria Lyttle, a 43-year-old mother from Newtownards, in Northern Ireland, turned to medical marijuana to manage her severe migraines, which have plagued her since childhood. With monthly prescription costs reaching up to 350 pounds sterling ($366), Toria's case underscores the ongoing challenges...

AbbVie Inc (NYSE: ABBV) has reported data from the Phase 3 PROGRESS trial of atogepant (Qulipta) for the preventive treatment of chronic migraine in adults. The trial met its primary endpoint of statistically significant reduction from baseline in mean monthly migraine days compared to...

Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN) and Pfizer Inc (NYSE: PFE) reported topline results from an Asia-Pacific, Phase 3 trial of rimegepant in adults for the acute treatment of migraine.  The study met its co-primary endpoints of freedom from pain...

ElectroCore Inc (NASDAQ: ECOR) announced the publication of a peer-reviewed paper entitled "Non-invasive vagus nerve stimulation (nVNS) for the prevention of migraine" in Cephalalgia, the official journal of the International Headache Society. The paper reports the results...

Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN) is eyeing filing for approval in early 2022 for its experimental pain spray after new data showed it hit its primary endpoints in a Phase 3 trial. The drug, zavegepant, a small-molecule CGRP receptor that can work as a spray...

The FDA has signed off Tonix Pharmaceuticals Holding Corp's (NASDAQ: TNXP) Investigational New Drug (IND) Application to initiate Phase 2 study of TNX-1900 for migraine.  TNX-1900 is intranasal potentiated oxytocin designed for the prevention of migraine headaches in...

Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN) and Pfizer Inc (NYSE: PFE) have announced an agreement for rimegepant in markets outside the U.S. Rimegepant is commercialized as Nurtec ODT in the U.S. and is indicated for the acute treatment of migraine attacks with or...

Cowen has raised Impel NeuroPharma Inc's (NASDAQ: IMPL) price target to $55 from $35, with an Outperform rating, after the FDA approved Trudhesa for the acute treatment of migraine. The analyst sees more than 100% upside for the stock. Related Content: FDA Gives Nod To...

The FDA has approved Impel NeuroPharma Inc's (NASDAQ: IMPL) Trudhesa (dihydroergotamine mesylate) nasal spray for the acute treatment of migraine with or without aura in adults.  Using Impel's Precision Olfactory Delivery technology, Trudhesa gently delivers...

Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) announced Wednesday that it has preliminary net revenue of approximately $93 million for its NURTEC ODT product in the second quarter of 2021. NURTEC ODT is an oral drug for the preventive treatment of episodic migraine. It's...

Nano-cap Zosano Pharma Corporation (NASDAQ: ZSAN) has announced that long-term data for Qtrypta, as an acute treatment of migraine, published in The Journal of Headache and Pain. The tolerability and efficacy results in this long-term study were consistent with the results...

Health Canada has approved ElectroCore Inc's (NASDAQ: ECOR) gammaCore Sapphire family of products to prevent and treat migraine and cluster headache. GammaCore Sapphire will be distributed in Canada by RSK Medical Inc, under an exclusive distribution agreement...

Shares of Alder Biopharmaceuticals Inc (NASDAQ: ALDR) hit a new 52-week low Wednesday for the second consecutive day as many investors found fault with the company's results from a phase 3 trial of its Eptinezumab therapy for the treatment of migraines. Piper Jaffray's Charles Duncan, Ph.D....

Shares of Alder Biopharmaceuticals Inc (NASDAQ: ALDR) lost more than 20 percent on Tuesday and hit a new 52-week low of $13.80 despite reporting positive results for its late-stage migraine prevention drug called eptinezumab. Eptinezumab was successful in meeting the primary and key secondary...

Shares of clinical-stage biopharmaceutical company Alder Biopharmaceuticals Inc (NASDAQ: ALDR) are up more than 100 percent from the lows they made in late April this year and are currently trading near their all-time highs. One of the main reasons for this surge has been the promising data...